LRP1 and esophageal squamous cell carcinoma: In esophageal squamous cell carcinoma, plasminogen activator inhibitor-1 (PAI-1) derived from CAF-like cells enhances migration and invasion abilities through the Akt-Erk1/2 signaling pathways via the PAI-1/low-density lipoprotein receptor-related protein 1 (LRP1) axis [140].